Using a pharmacologically optimized enzyme, PEGylated kynureninase, one study demonstrated that peritumoral injection slowed B16 and CT26 tumor growth in a CD8+ T cell–dependent manner (74). This evidence concerns the gene CD8A and neoplasm.